AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology and neuroscience – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Update: AbbVie headquarters building in California

Business

AbbVie Ends I-Mab Deal for CD47 Antibody Compounds, Products

After dropping an early-stage study more than a year ago, AbbVie has finally terminated its CD47 collaboration with I-Mab, leaving up to $1.3 billion in potential milestone payments on the table.

September 25, 2023

2 min read

Tristan Manalac

Pictured: Series of outcroppings with steep cliffs

Drug Development

Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?

In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.

September 15, 2023

2 min read

Greg Slabodkin

Pictured: AbbVie Corporate Office/iStock, vzphotos

Business

AbbVie Passes on License Option for Harpoon’s TriTAC Multiple Myeloma Program

The company declined to exercise the license option for Harpoon Therapeutics’ TriTAC HPN217 program for multiple myeloma, which targets B cell maturation antigen, or BCMA.

September 14, 2023

2 min read

Tristan Manalac

Drug Development

AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial

Continuing its clinical win streak, AbbVie’s Skyrizi showed signs of superiority against Johnson & Johnson’s Stelara in topline data from a head-to-head Phase III Crohn’s disease study.

September 13, 2023

2 min read

Tristan Manalac

AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report

As biosimilars and next-generation treatments for Crohn’s disease enter the market, AbbVie will be knocked from its place of longtime dominance, contends data and analytics firm GlobalData.

September 8, 2023

3 min read

Kate Goodwin

AbbVie Removes Two Early-Stage Cancer Assets from Pipeline

The company appears to be terminating the development of two Phase I antibody-drug conjugates in cancer, ABBV-011 and the Pfizer-partnered ABBV-647.

August 24, 2023

2 min read

Tristan Manalac

Pictured: Dubai skyline/Courtesy, iStock, MAGNIFIE

Business

Abu Dhabi, Dubai Serve as Gateway to International Markets for Biopharma

Burjeel Holdings and BridgeBio Pharma ink partnership deal in rare genetic diseases with a plan to set up headquarters in Abu Dhabi.

July 11, 2023

4 min read

Lisa Munger

Pictured: Pre-filled injector device/iStock, sunny

First Round of Humira Biosimilar Launches in US

AbbVie’s Humira will now face competition from new biosimilars, including Boehringer Ingelheim’s Cyltezo, Celltrion’s Yuflyma, Organon and Samsung’s Hadlima, and Sandoz’s Hyrimoz.

July 3, 2023

2 min read

Tristan Manalac

Pictured: AbbVie sign on a building/courtesy of Ad

Drug Development

AbbVie, Genmab Bi-Specific Lymphoma Data Tee Up Potential Challenge to Roche Drug

Phase I/II data on AbbVie and Genmab’s recently approved bi-specific antibody in a second cancer indication positions them to talk to regulators about filings to challenge Roche’s Lunsumio.

June 29, 2023

2 min read

Nick Paul Taylor

JOBS